MIST
Milestone Pharmaceuticals Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
3.05
P/S
84.44
EV/EBITDA
-1.93
DCF Value
$0.15
FCF Yield
-37.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
96.2%
Operating Margin
-4030.2%
Net Margin
-4078.8%
ROE
-656.8%
ROA
-55.5%
ROIC
-62.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $1.5M | $-17.4M | $-0.16 |
| FY 2025 | $1.5M | $-63.1M | $-0.75 |
| Q3 2025 | $0.00 | $-11.9M | $-0.12 |
| Q2 2025 | $0.00 | $-13.0M | $-0.20 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
CA
Exchange
NASDAQ
Beta
0.69
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.